dc.contributor.author |
Alaouna, Mohammed
|
|
dc.contributor.author |
Penny, Clement
|
|
dc.contributor.author |
Hull, Rodney
|
|
dc.contributor.author |
Molefi, Thulo
|
|
dc.contributor.author |
Chauke-Malinga, Nkhensani
|
|
dc.contributor.author |
Khanyile, Richard
|
|
dc.contributor.author |
Makgoka, Malose
|
|
dc.contributor.author |
Bida, Meshack
|
|
dc.contributor.author |
Dlamini, Zodwa
|
|
dc.date.accessioned |
2024-09-13T13:05:09Z |
|
dc.date.available |
2024-09-13T13:05:09Z |
|
dc.date.issued |
2023-06-16 |
|
dc.description.abstract |
Triple negative breast cancer (TNBC) is a very aggressive subtype of breast cancer that
lacks estrogen, progesterone, and HER2 receptor expression. TNBC is thought to be produced by
Wnt, Notch, TGF-beta, and VEGF pathway activation, which leads to cell invasion and metastasis.
To address this, the use of phytochemicals as a therapeutic option for TNBC has been researched.
Plants contain natural compounds known as phytochemicals. Curcumin, resveratrol, and EGCG are
phytochemicals that have been found to inhibit the pathways that cause TNBC, but their limited
bioavailability and lack of clinical evidence for their use as single therapies pose challenges to
the use of these phytochemical therapies. More research is required to better understand the role
of phytochemicals in TNBC therapy, or to advance the development of more effective delivery
mechanisms for these phytochemicals to the site where they are required. This review will discuss
the promise shown by phytochemicals as a treatment option for TNBC. |
en_US |
dc.description.department |
Anatomical Pathology |
en_US |
dc.description.department |
Medical Microbiology |
en_US |
dc.description.department |
Surgery |
en_US |
dc.description.librarian |
am2024 |
en_US |
dc.description.sdg |
SDG-03:Good heatlh and well-being |
en_US |
dc.description.sponsorship |
The South African Medical Research Council (SAMRC) and the National Research Foundation (NRF). |
en_US |
dc.description.uri |
https://www.mdpi.com/journal/plants |
en_US |
dc.identifier.citation |
Alaouna, M.; Penny, C.;
Hull, R.; Molefi, T.; Chauke-Malinga,
N.; Khanyile, R.; Makgoka, M.; Bida,
M.; Dlamini, Z. Overcoming the
Challenges of Phytochemicals in
Triple Negative Breast Cancer
Therapy: The Path Forward. Plants
2023, 12, 2350. https://DOI.org/10.3390/plants12122350. |
en_US |
dc.identifier.issn |
2223-7747 (online) |
|
dc.identifier.other |
10.3390/plants12122350 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/98226 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
MDPI |
en_US |
dc.rights |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. |
en_US |
dc.subject |
Phytomedicine |
en_US |
dc.subject |
Tyrosine kinase |
en_US |
dc.subject |
Wnt |
en_US |
dc.subject |
Epithelial to mesenchymal transition |
en_US |
dc.subject |
Angiogenesis |
en_US |
dc.subject |
Metastasis |
en_US |
dc.subject |
Apoptosis |
en_US |
dc.subject |
Triple negative breast cancer (TNBC) |
en_US |
dc.subject |
Breast cancer |
en_US |
dc.subject |
SDG-03: Good health and well-being |
en_US |
dc.title |
Overcoming the challenges of phytochemicals in triple negative breast cancer therapy : the path forward |
en_US |
dc.type |
Article |
en_US |